sorafenib has been researched along with quinoxalines in 5 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (quinoxalines) | Trials (quinoxalines) | Recent Studies (post-2010) (quinoxalines) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 9,887 | 625 | 3,095 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 4 (80.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, F; Richmond, A; Smykla, R; Thu, YM; Yang, J; Zaja-Milatovic, S | 1 |
| Capelletti, MM; Manceau, H; Peoc'h, K; Puy, H | 1 |
| Alanazi, MM; Alanazi, WA; Alasmari, AF; Albassam, H; Alsaif, NA; Elwan, A; Mahdy, HA; Obaidullah, AJ; Taghour, MS | 1 |
| Al-Hossaini, AM; Al-Mehizi, AA; Alanazi, MM; Alkahtani, HM; Alsaif, NA; Elwan, A; Mahdy, HA; Obaidullah, AJ; Taghour, MS | 1 |
| Abulkhair, HS; Eissa, IH; El-Adl, K; Mehany, ABM; Sakr, HM; Yousef, RG | 1 |
1 review(s) available for sorafenib and quinoxalines
| Article | Year |
|---|---|
Ferroptosis in Liver Diseases: An Overview.
Topics: alpha-Tocopherol; Animals; Autophagy; Chemical and Drug Induced Liver Injury; Cyclohexylamines; Cysteine; Ferroptosis; Glutathione; Heme; Humans; Iron; Kelch-Like ECH-Associated Protein 1; Lipid Peroxidation; Lipoxygenase; Liver Diseases; Liver Neoplasms; Oxidative Stress; Phenylenediamines; Phospholipid Hydroperoxide Glutathione Peroxidase; Piperazines; Quinoxalines; Reactive Oxygen Species; Reperfusion Injury; Signal Transduction; Sorafenib; Spiro Compounds; Sulfasalazine; Tumor Suppressor Protein p53 | 2020 |
4 other study(ies) available for sorafenib and quinoxalines
| Article | Year |
|---|---|
Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Dacarbazine; Drug Delivery Systems; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Melanoma; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Biological; Niacinamide; Phenylurea Compounds; Pyridines; Quinoxalines; Skin Neoplasms; Sorafenib; Substrate Specificity; Temozolomide; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
Design, synthesis and molecular docking of new [1,2,4] triazolo[4,3-a]quinoxaline derivatives as anticancer agents targeting VEGFR-2 kinase.
Topics: Antineoplastic Agents; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; MCF-7 Cells; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Quinoxalines; Sorafenib; Structure-Activity Relationship; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2022 |
Targeting VEGFR-2 by new quinoxaline derivatives: Design, synthesis, antiproliferative assay, apoptosis induction, and in silico studies.
Topics: Animals; Antineoplastic Agents; Apoptosis; Computer Simulation; Female; Hep G2 Cells; Humans; Inhibitory Concentration 50; MCF-7 Cells; Mice; Quinoxalines; Rats; Sorafenib; Structure-Activity Relationship; Triazoles; Vascular Endothelial Growth Factor Receptor-2 | 2022 |
New quinoxalin-2(1H)-one-derived VEGFR-2 inhibitors: Design, synthesis, in vitro anticancer evaluations, in silico ADMET, and docking studies.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Cell Proliferation; Drug Design; Humans; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Quinoxalines; Sorafenib; Structure-Activity Relationship; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2022 |